||||||||||UD TGFbetai NK cells / The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) Enrollment open, Preclinical, Combination therapy, Metastases: Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain (clinicaltrials.gov) - Dec 29, 2022 P1/2, N=30, Recruiting, Sponsor: Kari Kendra Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting